Marta Chesi

List of Publications by Year
in descending order

60 papers	6,221 citations	257357 24 h-index	206029 48 g-index
62 all docs	62 docs citations	62 times ranked	10907 citing authors

#	Article	IF	Citations
1	BET Bromodomain Inhibition asÂa Therapeutic Strategy to Target c-Myc. Cell, 2011, 146, 904-917.	13.5	2,432
2	Promiscuous Mutations Activate the Noncanonical NF-ÎºB Pathway in Multiple Myeloma. Cancer Cell, 2007, 12, 131-144.	7.7	941
3	Genetics and Cytogenetics of Multiple Myeloma. Cancer Research, 2004, 64, 1546-1558.	0.4	642
4	AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies. Cancer Cell, 2008, 13, 167-180.	7.7	322
5	Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia, 2014, 28, 1725-1735.	3.3	221
6	Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood, 2012, 120, 376-385.	0.6	174
7	Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment. Cancer Cell, 2018, 33, 634-648.e5.	7.7	163
8	Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression. Nature Communications, 2018, 9, 4832.	5.8	144
9	IAP antagonists induce anti-tumor immunity in multiple myeloma. Nature Medicine, 2016, 22, 1411-1420.	15.2	133
10	Immunosurveillance and therapy of multiple myeloma are CD226 dependent. Journal of Clinical Investigation, 2015, 125, 2077-2089.	3.9	111
11	MYC dysregulation in the progression of multiple myeloma. Leukemia, 2020, 34, 322-326.	3.3	108
12	TPL2 kinase regulates the inflammatory milieu of the myeloma niche. Blood, 2014, 123, 3305-3315.	0.6	89
13	Blocking IFNAR1 inhibits multiple myelomaâ€"driven Treg expansion and immunosuppression. Journal of Clinical Investigation, 2018, 128, 2487-2499.	3.9	80
14	Transcriptional repression by the HDAC4â€"RelBâ€"p52 complex regulates multiple myeloma survival and growth. Nature Communications, 2015, 6, 8428.	5.8	53
15	Bone marrow transplantation generates T cellâ€"dependent control of myeloma in mice. Journal of Clinical Investigation, 2018, 129, 106-121.	3.9	49
16	Many Multiple Myelomas: Making More of the Molecular Mayhem. Hematology American Society of Hematology Education Program, 2011, 2011, 344-353.	0.9	46
17	Antigen-mediated regulation in monoclonal gammopathies and myeloma. JCI Insight, 2018, 3, .	2.3	43
18	<i>UCHL1</i>is a biomarker of aggressive multiple myeloma required for disease progression. Oncotarget, 2015, 6, 40704-40718.	0.8	39

#	Article	IF	Citations
19	Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination. Leukemia, 2020, 34, 245-256.	3.3	38
20	Inhibitors of the protein disulfide isomerase family for the treatment of multiple myeloma. Leukemia, 2019, 33, 1011-1022.	3.3	37
21	Tumor Burden Limits Bispecific Antibody Efficacy through T-cell Exhaustion Averted by Concurrent Cytotoxic Therapy. Blood Cancer Discovery, 2021, 2, 354-369.	2.6	37
22	Multiple myeloma cellsâ€™ capacity to decompose H2O2 determines lenalidomide sensitivity. Blood, 2017, 129, 991-1007.	0.6	33
23	MiR-16 regulates crosstalk in NF-ÎºB tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages. JCI Insight, 2019, 4, .	2.3	33
24	Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma. OncoImmunology, 2015, 4, e1008850.	2.1	27
25	Identification of PIKfyve kinase as a target in multiple myeloma. Haematologica, 2020, 105, 1641-1649.	1.7	25
26	Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma. Cancer Immunology Research, 2015, 3, 881-890.	1.6	24
27	Monosomic Loss of MIR15A/MIR16-1 Is a Driver of Multiple Myeloma Proliferation and Disease Progression. Blood Cancer Discovery, 2020, 1, 68-81.	2.6	24
28	Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model. Blood Advances, 2019, 3, 797-812.	2.5	22
29	Expression of <i>Nras</i> <i>Q61R</i> and <i>MYC</i> transgene in germinal center B cells induces a highly malignant multiple myeloma in mice. Blood, 2021, 137, 61-74.	0.6	21
30	Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model. JCI Insight, 2019, 4, .	2.3	20
31	Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers. Leukemia Research, 2014, 38, 948-954.	0.4	14
32	Longitudinal single-cell analysis of a myeloma mouse model identifies subclonal molecular programs associated with progression. Nature Communications, 2021, 12, 6322.	5.8	12
33	Phase II trial of nabâ€paclitaxel in patients with relapsed or refractory multiple myeloma. American Journal of Hematology, 2016, 91, E504-E505.	2.0	6
34	Promiscuous mechanisms underlie the antitumor effects of thalidomide analogs. Nature Medicine, 2016, 22, 706-707.	15.2	5
35	Inhibition Of RNA Polymerase I Transcription By CX-5461 As a Therapeutic Strategy For The Cancer-Specific Activation Of p53 In Highly Refractory Haematological Malignancies. Blood, 2013, 122, 3941-3941.	0.6	4
36	Mice Expressing MYC and NrasQ61R in Germinal Center B Cells Develop Highly Aggressive Multiple Myeloma. Blood, 2018, 132, 1006-1006.	0.6	3

#	Article	IF	Citations
37	Antibodies Create Killer Bonds in Myeloma. Cancer Cell, 2017, 31, 305-307.	7.7	2
38	Importin-Î² and exportin-5 are strong biomarkers of productive reoviral infection of cancer cells. Annals of Diagnostic Pathology, 2018, 32, 28-34.	0.6	2
39	A Single-Cell Transcriptional Analysis of Tumour Cells and the Immune Microenvironment during Disease Evolution in a Transgenic Mouse Model of Myeloma. Blood, 2018, 132, 56-56.	0.6	2
40	The Murine Vk*MYC Myeloma Shares Defining Genetic Lesions with Human Multiple Myeloma.. Blood, 2009, 114, 1808-1808.	0.6	2
41	Transplantation of autologous bone marrow pre-loaded <i>ex vivo</i> with oncolytic myxoma virus is efficacious against drug-resistant Vk*MYC mouse myeloma. Oncotarget, 2022, 13, 490-504.	0.8	2
42	A Novel Transgenic Mouse Model of Multiple Myeloma Reliably Predicts Drug Response.. Blood, 2006, 108, 241-241.	0.6	1
43	Activation of MYC Pathway Is a Unifying Pathological Event in the Progression from Monoclonal Gammopathy of Undetermined Significance (MGUS) to Myeloma (MM).. Blood, 2007, 110, 241-241.	0.6	1
44	PARP Inhibition (OLAPARIB) Enhance Melphalan and Nutlin-3a Sensitivity in TP53 Positive Multiple Myeloma. Blood, 2012, 120, 1846-1846.	0.6	1
45	Promiscuous Cryptic Rearrangements of the MYC Locus Cis-Dysregulate MYC Expression and Are Present in the Majority of Patients with Hyperdiploid Myeloma. Blood, 2012, 120, 724-724.	0.6	1
46	Genome Wide Studies in Multiple Myeloma Identify XPO1/CRM-1 As a Critical Target Validated Using the Selective Inhibitor of Nuclear Export (SINE) KPT-276. Blood, 2012, 120, 573-573.	0.6	1
47	Altered Iron Metabolism Is a New Targetable Hallmark for Multiple Myeloma. Blood, 2019, 134, 3059-3059.	0.6	1
48	Cancer/Testis Antigen Profiling in Multiple Myeloma Define a Cohort of Patients with Poor Prognosis Regardless of Genetic Subtypes.. Blood, 2005, 106, 3381-3381.	0.6	0
49	The Multiple Myeloma SET Domain (MMSET) Protein Is a Histone H3 and H4 Methyltransferase with Properties of a Transcriptional Co-Repressor.. Blood, 2005, 106, 358-358.	0.6	0
50	High Resolution Array CGH Identifies TRAF3 as a Novel Tumor Suppressor in Multiple Myeloma.. Blood, 2006, 108, 3407-3407.	0.6	0
51	Inhibition of c-Myc Expression and Function in Hematologic Malignancies. Blood, 2011, 118, 1409-1409.	0.6	0
52	Examining Measures of Proliferation for Use in Risk Stratification of Myeloma. Blood, 2011, 118, 5093-5093.	0.6	0
53	Donor T Cells Maintain Myeloma-Immune Equilibrium after Autologous Stem Cell Transplantation and Concurrent Immunotherapy Promotes Cure. Blood, 2018, 132, 2031-2031.	0.6	0
54	Reconstructing the Clonal and Mutational Architecture of Myeloma through Avian Leukosis Virus (ALV)-Mediated Genome Editing. Blood, 2018, 132, 4480-4480.	0.6	0

#	Article	IF	Citations
55	Myeloma Cells Addicted to Glutamine for Biomass Production Are Sensitive to Lenalidomide. Blood, 2019, 134, 4410-4410.	0.6	0
56	Disrupting Ectopic Super-Enhancers to Treat Multiple Myeloma. Blood, 2021, 138, 1593-1593.	0.6	0
57	Aberrant CDK7 Activity Drives the Cell Cycle and Transcriptional Dysregulation to Support Multiple Myeloma Growth: An Attractive Molecular Vulnerability. Blood, 2021, 138, 2687-2687.	0.6	0
58	Selective Cell State in the Clonally Expanded T-Cell Compartment of VÎº*MYC Mice Responding to Treatment with Checkpoint Inhibitors. Blood, 2021, 138, 1581-1581.	0.6	0
59	Targeting MM at the Nexus between Cell Cycle and Transcriptional Regulation Via CDK7 Inhibition. Blood, 2020, 136, 1-2.	0.6	0
60	Monosomic Loss of MIR15A/MIR16-1 Is a Driver of Multiple Myeloma Proliferation and Disease Progression. Blood Cancer Discovery, 2020, 1, 68-81.	2.6	0